Johnson & Johnson Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Johnson & Johnson Bundle
Unlock Strategic Clarity
Johnson & Johnson sits at an interesting crossroads — a mix of global powerhouses, niche healers, and a few units that need hard choices. Our quick read shows where market share and growth collide, but it’s just the surface. Buy the full BCG Matrix to get quadrant-by-quadrant placement, data-backed recommendations, and an executable plan. Get the complete Word + Excel package and move from insight to action fast.
Stars
Darzalex (multiple myeloma)
Darzalex is the leader in the fast-growing multiple myeloma segment with strong clinical pull, reporting roughly $7.9B in 2024 sales and high-teens percentage year-over-year growth as usage deepens across lines of therapy. It keeps taking share as frontline and combination regimens expand, but growth remains capital-intensive with elevated reinvestment needs. Hold the line: sustained reinvestment can compound Darzalex into a powerhouse cash engine for J&J.
Tremfya (immunology)
Tremfya is gaining ground in psoriasis and psoriatic arthritis with clean Phase 3 and real‑world tolerability and simple dosing, helping it capture significant switch share; 2024 global sales reached about $4.1 billion while the psoriasis biologics category is ~22 billion USD and still expanding. Marketing and access spend remain justified—continued investment to fuel uptake is critical to cement leadership before new rivals enter.
Carvykti (CAR-T, myeloma)
Carvykti sits in the Stars quadrant as explosive demand drives rapid uptake: CARTITUDE-1 showed an overall response rate ~98% with deep, durable remissions, attracting clinicians and payers and creating a market accelerating into 2024. Limited direct CAR-T peers in myeloma and strong real-world adoption support defendable share if capacity scales. Johnson & Johnson should invest heavily in manufacturing and cold-chain logistics to unlock the full commercial curve. Capacity ramping and site activation are the key value levers.
Opsumit & Uptravi (pulmonary hypertension)
Opsumit and Uptravi sit in a durable, expanding PAH niche where prevalence is estimated at 15–50 cases per million and incidence 2–7 per million annually, supporting steady patient-level demand in 2024. Strong physician loyalty and real-world outcome data have sustained market share gains and adherence. The franchise’s breadth across prostacyclin and endothelin mechanisms plus ongoing lifecycle and access programs continue to drive uptake.
- Durable niche: PAH prevalence 15–50/million (2024)
- Defensive factors: physician loyalty, real-world outcomes
- Breadth: multiple lines/mechanisms (prostacyclin, endothelin)
- Support: lifecycle management and access programs maintaining growth
Biosense Webster (AFib ablation)
Biosense Webster is the category leader in electrophysiology mapping and AFib ablation within Johnson & Johnson, benefiting from secular tailwinds as AFib affects ~6 million Americans and an estimated 59 million people globally; procedure volumes and tech adoption have continued upward into 2024. High switching costs, strong ecosystem integration, and entrenched training programs protect share; continued investment in innovation and operator training widens the moat.
- Market position: leader in EP mapping and ablation
- Demand drivers: AFib prevalence ~6M US, ~59M global
- Growth: rising procedure volumes and adoption in 2024
- Moat: ecosystem, training, high switching costs; back R&D/training
7.9B, ~98% ORR, AFib 6M
Stars: Darzalex $7.9B (2024) with high‑teens growth; Tremfya $4.1B (2024) capturing psoriasis share; Carvykti ~98% ORR driving rapid CAR-T uptake; Biosense Webster benefits from AFib prevalence ~6M US/59M global; Opsumit/Uptravi serve PAH niche (15–50/million).
| Asset | 2024/$ | Key metric |
|---|---|---|
| Darzalex | 7.9B | High‑teens % growth |
| Tremfya | 4.1B | Large psoriasis share |
| Carvykti | — | ~98% ORR |
| Biosense | — | AFib 6M US/59M global |
What is included in the product
Detailed Word Document
BCG analysis of Johnson & Johnson products: stars, cash cows, question marks and dogs with investment, divestment and risk guidance.
Customizable Excel Spreadsheet
One-page Johnson & Johnson BCG Matrix highlighting business pain points for quick C-level decisions
Cash Cows
Stelara (immunology)
Stelara (ustekinumab) sits on a massive, high-margin base—generating roughly $8 billion in 2023—and dominates a mature immunology segment. Growth is moderating to low-single-digit rates as LOE dynamics and regional competitive entry approach. It continues to throw off substantial cash with modest promotion, so J&J can milk near-term cashflows while steering patients toward next-generation assets.
Xarelto (anticoagulant, U.S.)
Xarelto remains a large-scale, high-share U.S. anticoagulant with estimated 2024 U.S. sales around $3.4 billion and a sticky script base despite DOAC competition. Promotion needs are lower as patient persistence and refill rates keep cash conversion strong; gross-to-net dynamics remain favorable. Focus on optimizing contracting, rebates and defending cardiology and primary-care prescriber cohorts to protect margin and share.
Ethicon Surgical (stapling & energy)
Ethicon Surgical (stapling & energy) is J&J’s core surgical toolkit, leveraging entrenched hospital relationships and long procurement contracts. The stapling and energy markets are mature, procurement-driven and predictably cyclical. Scale and manufacturing efficiency generate steady cash flow for Medical Devices. Ongoing incremental product innovation and robust field support sustain high utilization and repeat purchasing.
DePuy Synthes (hips, knees, trauma)
DePuy Synthes leverages a significant installed base and strong surgeon loyalty across hips, knees and trauma, underpinning steady demand; J&J Medical Devices reported roughly $24.6 billion in 2024, with orthopedics a major contributor. Mix shifts and pricing pressure are manageable given scale and distribution reach, keeping margins resilient. Cash flow remains reliable despite modest procedure growth; focus is on ops excellence and selective premiumization to sustain returns.
- Installed base: durable market position
- 2024 Med Devices rev: ~$24.6B
- Scale offsets pricing/mix pressure
- Reliable cash flow with modest volume growth
- Strategy: ops excellence + targeted premiumization
ACUVUE (vision care)
ACUVUE is a cash cow for Johnson & Johnson, holding a leading share in the global soft contact lens category with strong brand equity and deep retail and professional channels that keep churn low; marketing spend is moderate relative to margins. Tight inventory management, incremental material and wear-time innovations, and steady distribution pricing maximize free cash flow.
- High-share brand
- Low churn via channel depth
- Moderate marketing intensity
- Keep supply tight
- Innovate edges
- Let cash roll
High-margin biologics, sticky Rx cash and $24.6B med-device scale fund R&D
Stelara generates very high-margin cash from a mature immunology base, allowing J&J to fund next-gen programs while growth moderates.
Xarelto (~$3.4B U.S. 2024) delivers sticky prescription cash with low promo intensity and focus on contracting to defend margins.
Ethicon/DePuy within Med Devices (2024 rev ~24.6B) provide steady, procurement-driven cash via installed bases and scale.
| Product | 2024 sales | Role |
|---|---|---|
| Stelara | high-$bn | Cash cow |
| Xarelto | $3.4B (US) | Cash cow |
| Med Devices | $24.6B | Cash generator |
| ACUVUE | major revenue | Stable cash |
Delivered as Shown
Johnson & Johnson BCG Matrix
The Johnson & Johnson BCG Matrix you're previewing is the exact file you'll receive after purchase. No watermarks, no placeholders—just the fully formatted strategic matrix tailored to J&J's portfolio. It’s ready to edit, print, or present straight away, backed by clear market insights and professional layout. Buy once, download instantly—no surprises, just actionable clarity.
Dogs
COVID-19 Vaccine (J&J)
Demand for the J&J (Janssen) COVID-19 vaccine has faded and its revenue contribution to Johnson & Johnson is minimal; by 2023–24 sales were largely immaterial to overall pharmaceuticals revenue. Market growth for COVID boosters is low and mRNA competitors Pfizer and Moderna have captured over 90% of global booster supply. Turnaround investment is unlikely to pay back; best to exit quietly and reallocate capital to higher-growth assets.
Tracleer (legacy pulmonary hypertension)
Tracleer (bosentan) is an older PAH asset within J&J facing clear erosion from generic entrants and reduced prescriber preference. Market growth for Tracleer is low with diminishing clinical share as newer therapies and generics dominate treatment pathways. Cash contribution is thin; prioritize an orderly wind-down and avoid rescue spend.
Invega franchise (post-LOE)
Post-LOE Invega faces generic competition that has taken roughly 80%+ of unit share and driven list prices down about 70% versus pre-LOE levels (2024 market observations), while the schizophrenia antipsychotic market shows limited growth (~1–2% CAGR). Differentiation has slipped as generics match core efficacy, so investment in aggressive promotion is not justified. Maintain only essential medical and supply support to harvest residual value and protect patient access.
Imbruvica (partnered; declining)
Imbruvica (partnered; declining) has seen competitive displacement in CLL erode both market share and growth as newer BTK alternatives and fixed-duration regimens gain adoption; incremental promotional spend is unlikely to reverse the downtrend. The CLL category is crowded with next-gen BTKs and combination therapies, compressing pricing and uptake. Prioritize margin preservation and cost discipline over chasing volume.
Legacy spine/trauma sub-lines under price pressure
Legacy spine/trauma sub-lines face commoditization and tender-driven pricing that capped growth and margins in 2024, with the global spinal implant market ~9 billion USD and accelerated price pressure in tender markets. Market share is fragmented and switching is frequent, making big turnarounds costly and slow; pruning SKUs and redeploying investment to higher-return platforms is advised.
- Commoditization: tender pricing reduced ASPs in key markets
- Fragmentation: frequent switching among suppliers
- Turnaround: large restructures take years and significant capex
- Action: prune low-return SKUs, shift to growth platforms
Boosters >90% to Pfizer/Moderna; Tracleer, Invega erode; spine price squeeze
J&J Dogs: COVID vaccine sales immaterial by 2023–24; Pfizer/Moderna >90% booster share. Tracleer facing generic erosion; PAH growth flat. Post‑LOE Invega generic share ~80%+, list prices down ~70% (2024). Legacy spine commoditized; spinal implant market ≈$9B with accelerated price pressure.
| Asset | 2024 metric | Recommendation |
|---|---|---|
| COVID vaccine | Booster share >90% competitors | Exit |
| Tracleer | Generic erosion | Wind‑down |
| Invega | Generic share ~80%+, price -70% | Harvest |
| Spine | Market ≈$9B; price pressure | Prune SKUs |
Question Marks
Rybrevant (EGFR-mutated NSCLC)
Rybrevant (amivantamab), approved in 2021 for EGFR exon 20 insertion NSCLC (a ~2% subset of NSCLC), remains a Question Mark for J&J: promising clinical data and potential label expansions could drive step-change adoption, but current commercial share is small in a crowded, evolving EGFR niche. Unlocking scale requires targeted investment in reflex diagnostics and payer access programs. J&J must scale fast by indication or reassess resource allocation.
Tecvayli (bispecific, myeloma)
Tecvayli (teclistamab), approved in 2022 for relapsed/refractory multiple myeloma, shows strong efficacy (MajesTEC-1 ORR ~63%), indicating room to grow earlier in the treatment journey. Manufacturing scale-up, CRS/neurologic safety management and site onboarding remain gating factors. Johnson & Johnson is spending heavily now with modest near-term returns; if uptake accelerates into front-line use, Tecvayli could flip to star status.
Talvey (bispecific, myeloma)
Talvey shows early traction in the high-growth relapsed/refractory multiple myeloma subsegment, where there are roughly 34,000 new US cases/year (2024) and significant unmet need. Awareness and operational support lags commercial potential, limiting uptake despite positive clinical signals. Cash burn is real as launch infrastructure and patient identification scale. Double down on centers of excellence to concentrate referrals and tip momentum.
MONARCH (robotic bronchoscopy)
MONARCH (robotic bronchoscopy) is a compelling advanced platform in a nascent, fast-growing interventional pulmonology segment; the technology traces to Auris Health, acquired by Johnson & Johnson for 3.4 billion USD in 2019, and the Monarch system gained FDA clearance for peripheral bronchoscopy in 2018.
Installed base and peer-reviewed evidence continue scaling through 2024, while capital sales cycles remain long and lumpy; commercial wins hinge on hard outcomes data, comprehensive operator training, and creative financing to lower acquisition barriers.
- Market tag: nascent, expanding clinical need
- Regulatory tag: FDA clearance 2018
- Commercial tag: long, lumpy capital cycles
- Go-to-market tag: outcomes, training, smart financing
VELYS (ortho robotics & digital)
Robotics in ortho grew ~20% YoY in 2024 and captured roughly 7% of US knee arthroplasties, but market share for VELYS remains early as surgeon habits are sticky; platform-driven implant pull-through is plausible if adoption expands. Focused OR placements and peer-reviewed proof of reduced OR time and improved outcomes are required. Invest selectively where clinical champions can drive network effects.
- MarketGrowth: +20% YoY (2024)
- Adoption: ~7% of US knees (2024)
- Barrier: surgeon inertia
- Need: OR time & outcomes evidence
- Strategy: selective investment with champions
Targeted drugs, bispecifics and surgical robots need scale, access and outcomes
Rybrevant (~2% EGFR ex20 NSCLC) has limited share; Tecvayli (MajesTEC‑1 ORR ~63%) needs manufacturing/site scale; Talvey shows traction in ~34,000 US MM cases/year (2024); MONARCH (Auris $3.4B 2019, FDA clear 2018) and VELYS (ortho robotics +20% YoY, ~7% US knees 2024) need outcomes, training and smart financing to become stars.
| Asset | 2024 datapoint | Key gap |
|---|---|---|
| Rybrevant | ~2% NSCLC | diagnostics, access |
| Tecvayli | ORR ~63% | scale, safety sites |
| Talvey | ~34,000 US MM | awareness, referrals |
| MONARCH/VELYS | Auris $3.4B; ortho +20% YoY; 7% knees | outcomes, training |